NCT05859334 2026-04-13
Testing the Anti-cancer Drug Erdafitinib for Brain Cancers That Have Returned or Progressed Following Treatment
National Cancer Institute (NCI)
Phase 2 Recruiting
National Cancer Institute (NCI)
Ohio State University Comprehensive Cancer Center